322 related articles for article (PubMed ID: 23832089)
1. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability.
Pajvani UB; Qiang L; Kangsamaksin T; Kitajewski J; Ginsberg HN; Accili D
Nat Med; 2013 Aug; 19(8):1054-60. PubMed ID: 23832089
[TBL] [Abstract][Full Text] [Related]
2. Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation.
Kenerson HL; Yeh MM; Yeung RS
PLoS One; 2011 Mar; 6(3):e18075. PubMed ID: 21479224
[TBL] [Abstract][Full Text] [Related]
3. Livers with constitutive mTORC1 activity resist steatosis independent of feedback suppression of Akt.
Kenerson HL; Subramanian S; McIntyre R; Kazami M; Yeung RS
PLoS One; 2015; 10(2):e0117000. PubMed ID: 25646773
[TBL] [Abstract][Full Text] [Related]
4. AMPK activation prevents excess nutrient-induced hepatic lipid accumulation by inhibiting mTORC1 signaling and endoplasmic reticulum stress response.
Li H; Min Q; Ouyang C; Lee J; He C; Zou MH; Xie Z
Biochim Biophys Acta; 2014 Sep; 1842(9):1844-54. PubMed ID: 25016145
[TBL] [Abstract][Full Text] [Related]
5. Hepatic mTOR-AKT2-Insig2 signaling pathway contributes to the improvement of hepatic steatosis after Roux-en-Y Gastric Bypass in mice.
Pan Q; Qin T; Gao Y; Li S; Li D; Peng M; Zhai H; Xu G
Biochim Biophys Acta Mol Basis Dis; 2019 Mar; 1865(3):525-534. PubMed ID: 30562559
[TBL] [Abstract][Full Text] [Related]
6. Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c.
Wan M; Leavens KF; Saleh D; Easton RM; Guertin DA; Peterson TR; Kaestner KH; Sabatini DM; Birnbaum MJ
Cell Metab; 2011 Oct; 14(4):516-27. PubMed ID: 21982711
[TBL] [Abstract][Full Text] [Related]
7. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways.
Yecies JL; Zhang HH; Menon S; Liu S; Yecies D; Lipovsky AI; Gorgun C; Kwiatkowski DJ; Hotamisligil GS; Lee CH; Manning BD
Cell Metab; 2011 Jul; 14(1):21-32. PubMed ID: 21723501
[TBL] [Abstract][Full Text] [Related]
8. Suppression of the mTORC1/STAT3/Notch1 pathway by activated AMPK prevents hepatic insulin resistance induced by excess amino acids.
Li H; Lee J; He C; Zou MH; Xie Z
Am J Physiol Endocrinol Metab; 2014 Jan; 306(2):E197-209. PubMed ID: 24302004
[TBL] [Abstract][Full Text] [Related]
9. Liver clock protein BMAL1 promotes de novo lipogenesis through insulin-mTORC2-AKT signaling.
Zhang D; Tong X; Arthurs B; Guha A; Rui L; Kamath A; Inoki K; Yin L
J Biol Chem; 2014 Sep; 289(37):25925-35. PubMed ID: 25063808
[TBL] [Abstract][Full Text] [Related]
10. Fisetin regulates obesity by targeting mTORC1 signaling.
Jung CH; Kim H; Ahn J; Jeon TI; Lee DH; Ha TY
J Nutr Biochem; 2013 Aug; 24(8):1547-54. PubMed ID: 23517912
[TBL] [Abstract][Full Text] [Related]
11. mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2.
Kim K; Qiang L; Hayden MS; Sparling DP; Purcell NH; Pajvani UB
Nat Commun; 2016 Jan; 7():10255. PubMed ID: 26743335
[TBL] [Abstract][Full Text] [Related]
12. Direct Hepatocyte Insulin Signaling Is Required for Lipogenesis but Is Dispensable for the Suppression of Glucose Production.
Titchenell PM; Quinn WJ; Lu M; Chu Q; Lu W; Li C; Chen H; Monks BR; Chen J; Rabinowitz JD; Birnbaum MJ
Cell Metab; 2016 Jun; 23(6):1154-1166. PubMed ID: 27238637
[TBL] [Abstract][Full Text] [Related]
13. DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease.
Chen H; Shen F; Sherban A; Nocon A; Li Y; Wang H; Xu MJ; Rui X; Han J; Jiang B; Lee D; Li N; Keyhani-Nejad F; Fan JG; Liu F; Kamat A; Musi N; Guarente L; Pacher P; Gao B; Zang M
Hepatology; 2018 Aug; 68(2):496-514. PubMed ID: 29457836
[TBL] [Abstract][Full Text] [Related]
14. Amino Acids Attenuate Insulin Action on Gluconeogenesis and Promote Fatty Acid Biosynthesis via mTORC1 Signaling Pathway in trout Hepatocytes.
Dai W; Panserat S; Plagnes-Juan E; Seiliez I; Skiba-Cassy S
Cell Physiol Biochem; 2015; 36(3):1084-100. PubMed ID: 26112996
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice.
Shum M; Bellmann K; St-Pierre P; Marette A
Diabetologia; 2016 Mar; 59(3):592-603. PubMed ID: 26733005
[TBL] [Abstract][Full Text] [Related]
16. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
[TBL] [Abstract][Full Text] [Related]
17. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.
Umemura A; Park EJ; Taniguchi K; Lee JH; Shalapour S; Valasek MA; Aghajan M; Nakagawa H; Seki E; Hall MN; Karin M
Cell Metab; 2014 Jul; 20(1):133-44. PubMed ID: 24910242
[TBL] [Abstract][Full Text] [Related]
18. Hepatic insulin resistance in ob/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation.
Sajan MP; Ivey RA; Lee MC; Farese RV
J Lipid Res; 2015 Jan; 56(1):70-80. PubMed ID: 25395359
[TBL] [Abstract][Full Text] [Related]
19. Tangshen formula attenuates hepatic steatosis by inhibiting hepatic lipogenesis and augmenting fatty acid oxidation in db/db mice.
Kong Q; Zhang H; Zhao T; Zhang W; Yan M; Dong X; Li P
Int J Mol Med; 2016 Dec; 38(6):1715-1726. PubMed ID: 27840945
[TBL] [Abstract][Full Text] [Related]
20. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c.
Hagiwara A; Cornu M; Cybulski N; Polak P; Betz C; Trapani F; Terracciano L; Heim MH; Rüegg MA; Hall MN
Cell Metab; 2012 May; 15(5):725-38. PubMed ID: 22521878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
